Key result
Review summarizes progress, design strategies, and immunization effects of new classical swine fever marker vaccines.
Why the study?
Traditional C-strain vaccines cannot distinguish between vaccinated and infected animals, prompting the development of classical swine fever marker vaccines.
Marker vaccines for Classical Swine Fever offer a promising strategy to distinguish between vaccinated and infected animals, aiding in disease eradication.
Marker vaccines may enable DIVA strategies for CSF eradication; leaves open the need for field validation before adoption.
Classical swine fever (CSF) is a severe disease that has caused serious economic losses for the global pig industry and is widely prevalent worldwide. In recent decades, CSF has been effectively controlled through compulsory vaccination with a live CSF vaccine (C strain). It has been successfully eradicated in some countries or regions. However, the re-emergence of CSF in Japan and Romania, where it had been eradicated, has brought increased attention to the disease. Because the traditional C-strain vaccine cannot distinguish between vaccinated and infected animals (DIVA), this makes it difficult to fight CSF. The emergence of marker vaccines is considered to be an effective strategy for the decontamination of CSF. This paper summarizes the progress of the new CSF marker vaccine and provides a detailed overview of the vaccine design ideas and immunization effects. It also provides a methodology for the development of a new generation of vaccines for CSF and vaccine development for other significant epidemics.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) conducted a review in Classical swine fever. Classical swine fever marker vaccines was evaluated. This review summarizes the progress, design strategies, and immunization effects of new classical swine fever marker vaccines to aid in disease eradication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: